An Artificial Intelligence System for the Detection of Bladder Cancer via Cystoscopy: A Multicenter Diagnostic Study
- PMID: 34473310
- PMCID: PMC8826636
- DOI: 10.1093/jnci/djab179
An Artificial Intelligence System for the Detection of Bladder Cancer via Cystoscopy: A Multicenter Diagnostic Study
Abstract
Background: Cystoscopy plays an important role in bladder cancer (BCa) diagnosis and treatment, but its sensitivity needs improvement. Artificial intelligence has shown promise in endoscopy, but few cystoscopic applications have been reported. We report a Cystoscopy Artificial Intelligence Diagnostic System (CAIDS) for BCa diagnosis.
Methods: In total, 69 204 images from 10 729 consecutive patients from 6 hospitals were collected and divided into training, internal validation, and external validation sets. The CAIDS was built using a pyramid scene parsing network and transfer learning. A subset (n = 260) of the validation sets was used for a performance comparison between the CAIDS and urologists for complex lesion detection. The diagnostic accuracy, sensitivity, specificity, and positive and negative predictive values and 95% confidence intervals (CIs) were calculated using the Clopper-Pearson method.
Results: The diagnostic accuracies of the CAIDS were 0.977 (95% CI = 0.974 to 0.979) in the internal validation set and 0.990 (95% CI = 0.979 to 0.996), 0.982 (95% CI = 0.974 to 0.988), 0.978 (95% CI = 0.959 to 0.989), and 0.991 (95% CI = 0.987 to 0.994) in different external validation sets. In the CAIDS vs urologists' comparisons, the CAIDS showed high accuracy and sensitivity (accuracy = 0.939, 95% CI = 0.902 to 0.964; sensitivity = 0.954, 95% CI = 0.902 to 0.983) with a short latency of 12 seconds, much more accurate and quicker than the expert urologists.
Conclusions: The CAIDS achieved accurate BCa detection with a short latency. The CAIDS may provide many clinical benefits, from increasing the diagnostic accuracy for BCa, even for commonly misdiagnosed cases such as flat cancerous tissue (carcinoma in situ), to reducing the operation time for cystoscopy.
© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Figures
Comment in
-
Does Artificial Intelligence Meaningfully Enhance Cystoscopy?J Natl Cancer Inst. 2022 Feb 7;114(2):174-175. doi: 10.1093/jnci/djab180. J Natl Cancer Inst. 2022. PMID: 34473299 Free PMC article. No abstract available.
-
Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology.J Urol. 2022 Aug;208(2):474-476. doi: 10.1097/JU.0000000000002755. Epub 2022 May 20. J Urol. 2022. PMID: 35593062 No abstract available.
References
-
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A.. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. - PubMed
-
- Burger M, Catto JW, Dalbagni G, et al.Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63(2):234–241. - PubMed
-
- Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al.Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–1403. - PubMed
-
- Babjuk M, Burger M, Comperat EM, et al.European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)–2019 update. Eur Urol. 2019;76(5):639–657. - PubMed
-
- Brausi M, Collette L, Kurth K, et al.; for the EORTC Genito-Urinary Tract Cancer Collaborative Group. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol. 2002;41(5):523–531. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
